Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1820-1827

  Mayburd, Anatoly L ^a   Martínez, Alfredo ^c   Sackett, Daniel ^b   Liu, Huaitian ^a   Shin, Joanna ^a   Tauler, Jordy ^a   Avis, Ingalill ^a   Mulshine, James L ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c INSTITUTO CAJAL   (Spain)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ACTIN; CIGLITAZONE; DOCEBENONE; LIPID; PHOSPHATIDYLINOSITOL 3 KINASE;

ACTIN FILAMENT; ACTIN POLYMERIZATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CENTER; CELL MOTILITY; COMPUTER PROGRAM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSKELETON; DEPOLYMERIZATION; DNA TRANSCRIPTION; DOWN REGULATION; DRUG BINDING AND TRANSPORT; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FAT INTAKE; FOCAL ADHESION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID ABSORPTION; LUNG CANCER; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR; ULTRAVIOLET RADIATION; WESTERN BLOTTING;

ACTINS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOSKELETON; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; LIPOXYGENASE INHIBITORS; MICROSCOPY, CONFOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 33645682189     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2149     Document Type: Article

References (35)

1. Pace E, Profita M, Melis M, et al. LTB4 is present in exudative pleural effusions and contributes actively to neutrophil recruitment in the inflamed pleural space. Clin Exp Immunol 2004;135:519-27.
2. Calzada C, Vericel E, Mitel B, Lagarde M. Stimulation of platelet aggregation in response to arachidonic acid hydroperoxide via phospholipase activation. Lipids 1999;34 Suppl:S295.
3. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005;127:1312-26.
4. Cunha JM, Sachs D, Canetti CA, Poole S, Ferreira SH, Cunha FQ. The critical role of leukotriene B4 in antigen-induced mechanical hyperalgesia in immunised rats. Br J Pharmacol 2003;139:1135-45.
5. Jones JE, Walker JL, Song Y, et al. Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2004;286: H1775-84.
6. Chen X, Wang S, Wu N, et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 2004;10:6703-9.
7. Runarsson G, Liu A, Mahshid Y, et al. Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells. Blood 2005;105:1274-9.
8. Catalano A, Caprari P, Soddu S, Procopio A, Romano M. 5-Lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking. FASEB J 2004;18:1740-2.
9. Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 1996;97:806-13.
10. Matuyama M, Yoshimura R, Mitsuhashi M, et al. Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol Rep 2005;14:73-9.
11. Werz O, Burkert E, Samuelsson B, Steinhilber D. Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 2002;99:1044-5.
12. Dixon RA, Diehl RE, Opas E, et al. Requirement of a 5-lipoxygenase- activating protein for leukotriene synthesis. Nature 1990;343:282-4.
13. Wickelgren I. Heart disease. Gene suggests asthma drugs may ease cardiovascular inflammation. Science 2004;303:941.
14. Manev R, Manev H. 5-Lipoxygenase as a putative link between cardiovascular and psychiatric disorders. Crit Rev Neurobiol 2004;16:181-6.
15. Zhao L, Funk CD. Lipoxygenase pathways in atherosclerosis. Trends Cardiovasc Med 2004;14:191-5.
16. Ishii K, Motoyoshi S, Kawata J, Nakagawa H, Takeyama K. A useful method for differential evaluation of anti-inflammatory effects due to cyclooxygenase and 5-lipoxygenase inhibitions in mice. Jpn J Pharmacol 1994;65:297-303.
17. Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, Miller MS. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 2002;128:525-32.
18. Gugliuccu A, Ranzato L, Scorrano L, et al. Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors. J Biol Chem 2002;277:31789-95.
19. Harris JE, Alferai WA, Meng J, Andersen KM. Five-lipoxygenase inhibitors reduce Panc-1 survival: synergism of MK886 with γ-linolenic acid. Adv Exp Med Biol 1999;469:505-10.
20. Ghosh J, Mayers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A 1998;95:13182-7.
21. La E, Kern JC, Atarod EB, Kehrer JP. Fatty acid release and oxidation are factors in lipoxygenase inhibitor-induced apoptosis. Toxicol Lett 2003;138:193-20.
22. Avis I, Hong SH, Martinez A, et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 2001;15:2007-9.
23. Datta K, Biswal SS, Kehrer JP. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem J 1999;340:371-5.
24. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.
25. Lowry OH, Rosbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265.
26. Avis I, Martinez A, Tauler J, et al. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res 2005;65:4181-90.
27. Semizarov D, Frost L, Sathy A, Kroeger P, Hlabert DN, Fesik SW. Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci U S A 2003;100:6347-52.
28. Ciszak L, Krawczenko A, Polzar B, Mannherz HG, Malicka-Blaszkiewicz M. Carp liver actin: isolation, polymerization and interaction with deoxyribonuclease I (DNase I). Biochim Biophys Acta 1999;1451:141-52.
29. Carvalho Pinto-Silva CR, Ferreira JF, Costa RH, Belli Filho P, Creppy EE, Matias WG. Micronucleus induction in mussels exposed to okadaic acid. Toxicon 2003;41:93-7.
30. Shang X, Shiono Y, Fujita Y, Oka S, Yamazaki Y. Synergistic enhancement of apoptosis by DNA- and cytoskeleton damaging agents: a basis for combination chemotherapy of cancer. Anticancer Res 2001;21:2585-9.
31. Kristian T, Bernardi P, Siesjo BK. Acidosis promotes the permeability transition in energized mitochondria: implications for reperfusion injury. J Neurotrauma 2001;18:1059-74.
32. Goncalves RP, Rodrigues DG, Maranhao RC. Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leuk Res 2005;29:955-8.
33. Ito I, Began G, Mohiuddin I, Saeki T, et al. Increased uptake of liposomal-DNA complexes by lung metastases following intravenous administration. Mol Ther 2003;7:409-18.
34. Hrzenjak A, Reicher H, Wintersperger A, et al. Inhibition of lung carcinoma cell growth by high density lipoprotein-associated α-tocopheryl-succinate. Cell Mol Life Sci 2004;61:1520-31.
35. Fraley TS, Tran TC, Corgan AM, et al. Phosphoinositide binding inhibits α-actinin bundling activity. J Biol Chem 2003;278:24039-45.